NanoVibronix, Inc. (NAOV): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a company like NanoVibronix, Inc. pioneers therapeutic ultrasound technology in the competitive medical device landscape, especially while reporting revenues around **$1.1 million** for the full year 2023?

This isn't merely about abstract innovation; it's about tangible products like PainShield® and UroShield® aiming to disrupt traditional treatments through unique surface acoustic wave applications.

Navigating the path from research to market viability presents hurdles, reflected in their Q1 2024 revenue of approximately **$248,000**, yet their persistence highlights crucial aspects of medtech commercialization.

Are you ready to understand the core technology, the people behind the vision, and precisely how this company generates revenue and aims for growth?

NanoVibronix, Inc. (NAOV) History

NanoVibronix's Founding Timeline

Year established

NanoVibronix was incorporated in 2003.

Original location

The company originated in Nesher, Israel, establishing its initial research and development base there. It later established a US headquarters in Elmsford, New York.

Founding team members

While specific details on the entire founding team can be sparse, Dr. Harold Jacob is widely recognized for his key role in inventing the core Surface Acoustic Wave (SAW) technology. Early leadership also included figures like Brian Murphy, guiding the initial phases.

Initial capital/funding

Like many medtech startups, initial funding likely involved a combination of private investment, seed capital, and potentially research grants to support the development of its novel ultrasound technology. Precise early figures are not commonly disclosed, but this phase was critical for foundational R&D.

NanoVibronix's Evolution Milestones

NanoVibronix's Transformative Moments

Transition from R&D to Commercialization

Securing FDA clearances for PainShield and UroShield marked a pivotal shift from primarily research and development activities towards building sales channels and generating revenue, a common yet challenging transition for medtech firms.

Going Public via Reverse Merger

The 2014 decision to merge with a public shell company provided faster access to public markets compared to a traditional IPO. This fundamentally changed its capital structure and operational complexity.

Navigating Market Adoption and Reimbursement

Ongoing efforts to secure broader market adoption and favorable reimbursement codes for its devices represent a continuous strategic challenge, shaping product focus and sales strategies throughout its history up to 2024. Understanding the company's direction requires looking at its core goals; you can learn more about the Mission Statement, Vision, & Core Values of NanoVibronix, Inc. (NAOV).

NanoVibronix, Inc. (NAOV) Ownership Structure

NanoVibronix operates as a publicly traded entity, meaning its shares are available for purchase on the open market, leading to a dispersed ownership structure primarily held by the general public alongside institutional investors and company insiders.

NanoVibronix, Inc.'s Current Status

As of the end of 2024, NanoVibronix, Inc. is a public company. Its common stock is listed and traded on the NASDAQ Capital Market under the ticker symbol NAOV.

NanoVibronix, Inc.'s Ownership Breakdown

Understanding the ownership distribution provides insights into shareholder influence and potential alignment of interests. The following table outlines the approximate ownership structure based on data available for the 2024 fiscal year.

This structure reflects a significant holding by the general public. For a deeper dive into the company's financial standing, consider Breaking Down NanoVibronix, Inc. (NAOV) Financial Health: Key Insights for Investors.

NanoVibronix, Inc.'s Leadership

Steering the company at the close of 2024 is a dedicated leadership team responsible for strategic direction and operational execution. Key figures guiding the organization include:

• Brian Murphy: Chief Executive Officer
• Stephen Scuderi: Chief Financial Officer
• William Stern: Chairman of the Board of Directors

This team's decisions and governance practices are crucial for navigating the medical device market and driving shareholder value.

NanoVibronix, Inc. (NAOV) Mission and Values

NanoVibronix is driven by a commitment to leveraging its proprietary Surface Acoustic Wave (SAW) technology to create innovative medical devices. Their core focus extends beyond simple product development towards enhancing patient quality of life through non-invasive therapeutic solutions.

NanoVibronix's Core Purpose

Official mission statement

While not always explicitly stated in a single formal sentence, the company's operational mission centers on the research, development, and commercialization of its unique low-frequency, low-intensity therapeutic ultrasound technology. They aim to deliver effective, drug-free treatments for pain management and wound healing directly to patients and through healthcare providers. Understanding their operational focus is crucial when evaluating their overall standing; you can delve deeper by Breaking Down NanoVibronix, Inc. (NAOV) Financial Health: Key Insights for Investors.

Vision statement

The long-term vision appears focused on establishing their SAW technology as a standard of care in targeted therapeutic areas. They aspire to be recognized globally as leaders in providing convenient, patient-administered ultrasound therapies that significantly improve health outcomes and reduce reliance on conventional pain relief methods.

Company slogan

NanoVibronix does not prominently feature a single, overarching company slogan in its public communications.

NanoVibronix, Inc. (NAOV) How It Works

The company designs, develops, and markets medical devices based on its proprietary low-intensity surface acoustic wave (SAW) technology. This technology delivers localized ultrasound energy to disrupt biofilms or alleviate pain non-invasively.

Product/Service Portfolio

Operational Framework

NanoVibronix operates primarily as a research, development, and marketing entity. Product manufacturing is outsourced to specialized contract manufacturers, allowing the company to focus resources on innovation and market access. Key operational activities include:

• Ongoing research and development to refine existing products and explore new applications for its SAW technology, representing a significant portion of operating expenses.
• Managing outsourced manufacturing relationships to ensure quality control and supply chain efficiency.
• Navigating complex regulatory pathways, securing and maintaining approvals like FDA clearance and CE Marks in target geographies.
• Building distribution networks through direct sales efforts and partnerships with medical device distributors globally. As detailed in the Mission Statement, Vision, & Core Values of NanoVibronix, Inc. (NAOV)., these operational steps align with their core objectives.
• Marketing and sales activities focused on educating healthcare providers and patients about the benefits of their technology. Revenue for 2024 was primarily driven by sales of PainShield and UroShield products.

Strategic Advantages

The company's competitive edge stems from several key factors. Its core Surface Acoustic Wave (SAW) technology is protected by patents, creating a barrier to entry for competitors seeking to replicate its mechanism of action. Obtaining regulatory clearances, such as FDA 510(k) for specific indications, validates the technology's safety and efficacy profile for those uses. Furthermore, the focus on non-invasive and drug-free solutions addresses significant unmet needs in large markets like chronic pain management and hospital-acquired infection prevention. This positioning potentially offers advantages over traditional pharmaceutical or more invasive treatment options.

NanoVibronix, Inc. (NAOV) How It Makes Money

NanoVibronix generates revenue primarily through the sale of its proprietary therapeutic ultrasound devices, designed for pain relief and prevention of urinary tract infections. The company focuses on commercializing its PainShield and UroShield products.

NanoVibronix, Inc.'s Revenue Breakdown

Based on data for the nine months ended September 30, 2024, product sales constitute the vast majority of the company's income.

NanoVibronix, Inc.'s Business Economics

The company's economic model hinges on manufacturing and selling its ultrasound devices. Key factors influencing profitability include:

• Cost of Goods Sold (COGS): Direct costs associated with producing the devices significantly impact gross margins. For the nine months ended September 30, 2024, the gross profit margin was approximately 49.7%, indicating that nearly half of the revenue covers production costs.
• Pricing Strategy: Products are sold through distributors and directly, impacting the final price point and margin capture. Pricing needs to balance market acceptance with covering high operational costs.
• Operating Expenses: Research and development (R&D) costs are substantial, reflecting ongoing innovation efforts, totaling $0.52 million for the nine months ended September 30, 2024. Selling, general, and administrative (SG&A) expenses are also significant, reaching $2.03 million in the same period, driven by sales efforts, marketing, and administrative overhead.

NanoVibronix, Inc.'s Financial Performance

NanoVibronix reported total revenues of $0.44 million for the nine months ended September 30, 2024, a decrease compared to the same period in the prior year. Despite achieving a gross profit of $0.22 million, high operating expenses led to an operating loss of $2.33 million. The net loss for the period was $2.32 million. These figures highlight the challenges the company faces in scaling revenue to cover its operational costs and achieve profitability. Understanding the investor base can provide further context; Exploring NanoVibronix, Inc. (NAOV) Investor Profile: Who’s Buying and Why? delves into this aspect. Continued focus on increasing sales volume and managing expenses is critical for future financial health.

NanoVibronix, Inc. (NAOV) Market Position & Future Outlook

NanoVibronix holds a niche position in the therapeutic ultrasound market, focusing on non-invasive solutions for pain relief and wound healing. Its future outlook hinges significantly on expanding market adoption for its core products and securing broader reimbursement coverage, navigating a landscape populated by larger, more established medical device companies.

Competitive Landscape

Opportunities & Challenges

Industry Position

Within the vast medical device industry, NanoVibronix operates as a micro-cap innovator focused specifically on surface acoustic wave technology for localized therapeutic applications. Its products like PainShield and UroShield target unmet needs in non-invasive pain management and catheter-associated urinary tract infection (CAUTI) prevention, differentiating it from competitors with broader portfolios or different technological approaches. The company's success relies heavily on demonstrating clinical efficacy and economic value to gain traction against established standards of care. Continued investment in research and development, alongside strategic commercialization efforts, is crucial for improving its standing, a factor closely tied to its financial health. For more details on its financial standing, consider Breaking Down NanoVibronix, Inc. (NAOV) Financial Health: Key Insights for Investors. As of early 2025, based on 2024 performance showing revenues around $1.1 million, the company remains in a growth and validation phase, needing to significantly scale sales to achieve profitability and solidify its market position.